指南与共识免疫规划慢病防控与筛查卫生政策与健康促进

美国50-59岁及≥60岁成人带状疱疹疫苗接种覆盖率(重组带状疱疹疫苗推荐前)

Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine.
指南 / 共识 · Am J Prev Med · 2020-05-07

基于2013-2017年美国国家健康访谈调查及2017年行为风险因素监测系统数据,评估重组带状疱疹疫苗广泛使用前成人带状疱疹疫苗(ZVL)覆盖率。50-59岁成人2017年覆盖率为5.7%,2013-2017年间无显著趋势变化;≥60岁成人覆盖率从2013年24.2%升至2017年34.9%。各州覆盖率差异明显,且年龄较大、过去12个月就诊4-9次及有固定医疗场所与接种可能性增加相关。

要点

  • 50-59岁成人ZVL覆盖率低(2017年5.7%),且2013-2017年无显著上升趋势。
  • ≥60岁成人ZVL覆盖率从2013年24.2%增至2017年34.9%,但各州差异大(26.0%-51.8%)。
  • 年龄较大、过去12个月就诊4-9次及有固定医疗场所与接种可能性增加相关。

核心结论

  • 在重组带状疱疹疫苗广泛使用前,美国50-59岁成人ZVL覆盖率低且无显著趋势变化,≥60岁成人覆盖率有所上升但各州差异明显。

研究设计与样本

  • 研究分析2013-2017年国家健康访谈调查数据估计全国ZVL覆盖率,并使用2017年行为风险因素监测系统数据评估各州覆盖率。

主要发现

  • 50-59岁成人ZVL覆盖率2017年为5.7%,2013-2017年间在4%至6%之间波动(趋势检验p>0.05)。
  • 50-59岁成人ZVL覆盖率各州从宾夕法尼亚州5.8%到南达科他州14.7%不等。
  • ≥60岁成人ZVL覆盖率2017年为34.9%,较2013年24.2%显著增加。
  • ≥60岁成人ZVL覆盖率2017年各州从密西西比州26.0%到佛蒙特州51.8%不等。
  • 2017年,年龄较大、过去12个月就诊4-9次及有固定医疗场所与50-59岁和≥60岁成人接种ZVL可能性增加显著相关。

临床怎么用

  • 医疗服务提供者应常规评估成人疫苗接种状态,并强烈推荐或提供所需疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2006, zoster vaccine live was recommended for adults aged ≥60 years. In 2011, zoster vaccine live was approved for use but not recommended for adults aged 50-59 years. This study assessed zoster vaccine live coverage among adults aged 50-59 years and ≥60 years. METHODS: Data from the 2013-2017 National Health Interview Surveys were analyzed in 2019 to estimate national zoster vaccine live coverage among adults aged ≥50 years. State-specific zoster vaccine live coverage among adults aged ≥50 years was assessed using 2017 Behavioral Risk Factor Surveillance System data. RESULTS: Among adults aged 50-59 years, zoster vaccine live coverage was 5.7% in 2017, ranging from 4% to 6% during 2013-2017 (test for trend, p>0.05). Zoster vaccine live coverage among adults aged 50-59 years ranged from 5.8% in Pennsylvania to 14.7% in South Dakota. By 2017, zoster vaccine live was received by 34.9% of adults aged ≥60 years, a significant increase from 24.2% in 2013. Zoster vaccine live coverage among adults aged ≥60 years in 2017 ranged from 26.0% in Mississippi to 51.8% in Vermont. In 2017, major characteristics significantly associated with increased likelihood of zoster vaccine live vaccination among adults aged 50-59 years and ≥60 years were older age, having 4 to 9 physician contacts in the past 12 months, and having a usual place for health care. CONCLUSIONS: This study provides an assessment of zoster vaccine live coverage among adults aged ≥50 years before the newly recommended recombinant zoster vaccine came into widespread use. Providers should routinely assess adults' vaccination status and strongly recommend or offer needed vaccines to their patients.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Lu PJ, Hung MC, Srivastav A, et al. Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine. Am J Prev Med. 2020. PMID: 32389533. doi:10.1016/j.amepre.2020.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。